A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (NCT02817633)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (89 Sites)
Showing the first 25 of 89 sites.
- GSK Investigational Site — Goodyear, Arizona
- GSK Investigational Site — Scottsdale, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Encinitas, California
- GSK Investigational Site — Fountain Valley, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — San Marcos, California
- GSK Investigational Site — Whittier, California
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — Aurora, Colorado
- GSK Investigational Site — Denver, Colorado
- GSK Investigational Site — New Haven, Connecticut
- GSK Investigational Site — Washington D.C., District of Columbia
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Sarasota, Florida
- GSK Investigational Site — Tampa, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Augusta, Georgia
- GSK Investigational Site — Arlington Heights, Illinois
- GSK Investigational Site — Chicago, Illinois
- GSK Investigational Site — Niles, Illinois
- GSK Investigational Site — Iowa City, Iowa
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers — St Louis, Missouri
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors — Birmingham, Alabama
- Hispanic Adapted and Culturally Relevant Exercising Together — Tucson, Arizona
- M7824 Related Adverse Effects in Adults With Cancer — Bethesda, Maryland
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Duarte, California
Explore by condition: All Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.